Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Norcross, Georgia
- Most recent report
- 8-K, filed Aug 14, 2026
- Incorporated
- Nevada
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 1133416
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company
Financials 8 of 64
News 8 of 246
- 8-K Quarterly results Aug 14, 2026
- 8-K Current report on a material event Aug 4, 2026
- 8-K Current report on a material event Jun 23, 2026
- 8-K Quarterly results May 15, 2026
- 8-K Quarterly results Mar 31, 2026
- 8-K Leadership change Mar 17, 2026
- 8-K Leadership change Jan 21, 2026
- 8-K Leadership change Jan 12, 2026
Prospectuses and Registrations 8 of 33
- S-3 Shelf registration statement Mar 31, 2026
- S-3 Shelf registration statement Apr 14, 2023
- S-8 Registration statement for an employee plan Mar 30, 2023
- S-8 Registration statement for an employee plan Nov 9, 2020
- S-3 Shelf registration statement May 11, 2020
- S-3 Shelf registration statement Aug 9, 2019
- FWP Free writing prospectus May 10, 2019
- 424B1 Apr 30, 2019
Proxies 8 of 25
- DEFA14A Extra proxy material Oct 13, 2026
- DEF 14A Proxy statement for a shareholder vote Oct 13, 2026
- PRE 14A Preliminary proxy statement Oct 2, 2026
- DEFA14A Extra proxy material Oct 22, 2025
- DEF 14A Proxy statement for a shareholder vote Oct 22, 2025
- DEFA14A Extra proxy material Dec 3, 2024
- DEF 14A Proxy statement for a shareholder vote Dec 3, 2024
- DEFA14A Extra proxy material Oct 6, 2023
Ownership 8 of 584
- SCHEDULE 13D/A Large holder reported an active stake, amended Aug 4, 2026
- 4 Insider reported a trade Aug 4, 2026
- 4 Insider reported a trade Jul 16, 2026
- 4 Insider reported a trade Jun 30, 2026
- 4 Insider reported a trade Jun 30, 2026
- 144 Notice of a proposed sale of restricted stock Jun 29, 2026
- 144 Notice of a proposed sale of restricted stock Jun 26, 2026
- 144 Notice of a proposed sale of restricted stock Jun 26, 2026
Other 8 of 48
- ARS Annual report sent to shareholders Oct 13, 2026
- EFFECT Notice that a registration became effective Apr 10, 2026
- CORRESP Reply to SEC staff Apr 8, 2026
- UPLOAD Comment letter from SEC staff Apr 6, 2026
- ARS Annual report sent to shareholders Oct 22, 2025
- ARS Annual report sent to shareholders Dec 3, 2024
- ARS Annual report sent to shareholders Oct 6, 2023
- EFFECT Notice that a registration became effective Apr 24, 2023
Everything here comes from Galectin Therapeutics Inc's own filings on SEC EDGAR. The filing list is rechecked every hour.